DelveInsight’s, “Wet Age-Related Macular Degeneration Pipeline Insight 2023,” report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Wet Age-Related Macular Degeneration pipeline landscape. It covers the Wet Age-Related Macular Degeneration pipeline drug profiles, including Wet Age-Related Macular Degeneration clinical trial and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Wet Age-Related Macular Degeneration pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Wet Age-Related Macular Degeneration clinical trial studies, NDA approvals (if any), and product development activities comprising the technology, Wet Age-Related Macular Degeneration (Wet-AMD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Wet Age-Related Macular Degeneration Pipeline Report
Explore more information on the latest breakthroughs in the Wet Age-Related Macular Degeneration treatment landscape of the report @ Wet Age-Related Macular Degeneration Pipeline Outlook
Recent Developmental Activities in the Wet Age-Related Macular Degeneration Treatment Landscape
Wet Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type. The wet/neovascular type affects approximately 10–15% of individuals with age-related macular degeneration but accounts for approximately 90% of all cases of severe vision loss from the disease. It causes 90% of severe vision loss in people with AMD. Everyone who gets wet AMD had dry AMD at one point.
Find the information related to the Wet Age-Related Macular Degeneration emerging therapies and companies @ Wet Age-Related Macular Degeneration Ongoing Clinical Trials Analysis
Wet Age-Related Macular Degeneration Emerging Drugs Profile
LY09004: Luye Pharma
LY09004, a biosimilar for Eylea, is a recombinant human vascular endothelial growth factor receptor-antibody fusion protein ophthalmic injection, indicated for neovascular wAMD, macular edema following RVO, DME and diabetic retinopathy (DR) in patients with DME, and visual impairment due to pathological myopia secondary to choroidal neovascularization (PM-CNV). It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Luye Pharma.
KSI-301: Kodiak Sciences
KSI-301 is a novel anti-VEGF biologic built on a propriety antibody biopolymer conjugate (ABC) platform. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of VEGF for up to 6 months. The unique properties of KSI- 301 aim to provide patients with long-term control of their wet AMD with improved vision outcomes while reducing the burden of frequent anti-VEGF injections. It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Kodiak Sciences.
GEM-103: Gemini Therapeutics
GEM103 is a full-length recombinant complement factor H (rCFH) protein, is believed to be the first ever recombinant native complement regulator. GEM103 delivered by intravitreal injection is designed to address both complement hyperactivity and restore retinal health in patients with AMD. It is currently in the Phase II stage of development for the treatment of wAMD and is being developed by Gemini Therapeutics.
Zimura: Iveric Bio
Zimura (avacincaptad pegol) is designed to inhibit complement factor C5 cleavage into C5a and C5b. By inhibiting the formation of complement C5 terminal fragments, Zimura may decrease the activation of inflammasomes and the formation of membrane attack complex (MAC). The drug is in Phase III clinical studies for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD) and in Phase II clinical studies for wet AMD, Stargardt disease, and polypoidal choroidal vasculopathy (PCV).
RC 28 E: RemeGen
RC 28 E is a chimeric decoy receptor trap-fusion protein that acts by dual blockade of vascular endothelial growth factor (VEGF) and fibroblast growth factor-2. As compared to single-target EGF inhibitors, RC 28 has the potential to more effectively inhibit the abnormal blood vessel growth implicated in various diseases through both VEGF and FGF pathways, potentially allowing for a better dosing profile.
BI 836880: Boehringer Ingelheim
BI 836880 is a humanized bispecific nanobody comprising blocking domains for VEGF and angiopoietin-2 (Ang2). BI 836880 is a potent and selective inhibitor of VEGF and Ang2. By binding to VEGF and Ang2, BI 836880 inhibits tumor angiogenesis and vascularization and enhances the tumor microenvironment to support T-cell trafficking and function in the tumor. BI 836880 is currently being investigated in Phase II clinical studies for solid tumors and in Phase I clinical studies to treat wet AMD and non-small cell lung cancer.
AAVCAGsCD59: Janssen Research and Development
AAVCAGsCD59 is gene therapy. This drug is currently being evaluated in FDA approved clinical trials to treat both dry and wAMD. HMR59 injected in the eye increases the ability of retina cells to make a soluble form of CD59 called sCD59. The soluble CD59 circulates within the retina to block complement from further damaging the retina. AAVCAGsCD59 is currently in the Phase I stage of development for the treatment of wAMD and is being developed by Janssen Research and Development.
Wet Age-Related Macular Degeneration Therapeutics Assessment
There are approx. 70+ key companies which are developing the therapies for Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e. phase III include, Luye Pharma.
For further information, refer to the detailed Wet Age-Related Macular Degeneration Unmet Needs, Analyst Views of the Report @ Wet Age-Related Macular Degeneration Treatment Landscape
Scope of the Wet Age-Related Macular Degeneration Pipeline Report
Table of Content
Get to know more information related to the Wet Age-Related Macular Degeneration Pipeline Therapies and Companies @ Wet Age-Related Macular Degeneration Market Drivers and Barriers
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/